Semax Research Timeline

Synthesis and early development

Researchers at the Institute of Molecular Genetics synthesized Semax as a modified fragment of adrenocorticotropic hormone (ACTH), specifically the 4-10 sequence. The design aimed to retain neurotropic activity while eliminating hormonal effects on cortisol production.

Initial pharmacological characterization

Seredenin et al. published early pharmacogenetic analyses examining Semax's effects on emotional stress responses in animal models, establishing a foundation for understanding its influence on stress-related pathways.

Ann Ist Super Sanita

Cognitive and attention research

A series of publications documented Semax's effects on attention, learning, and memory in experimental models. Researchers noted modulation of dopaminergic and serotonergic systems without the hormonal side effects associated with full-length ACTH.

Nootropic and analgesic effects documented

Ashmarin et al. published findings on Semax's nootropic and analgesic properties, describing effects on conditioned reflex activity and pain threshold in animal models. This study helped characterize the compound's multi-pathway activity profile.

Zh Vyssh Nerv Deiat Im I P Pavlova

BDNF regulation demonstrated

Dolotov et al. published a landmark study showing that Semax regulates BDNF (brain-derived neurotrophic factor) and TrkB receptor expression in rat hippocampus and cortex. This research established a molecular mechanism connecting Semax to neurotrophic signaling.

Brain Res

Neuroprotection research expands

Multiple studies examined Semax in experimental stroke and brain injury models. Researchers documented effects on gene expression patterns associated with inflammation, apoptosis, and neuronal survival in ischemia models.

Transcriptomic profiling

Gene expression studies using microarray technology revealed that Semax affects the expression of hundreds of genes in brain tissue, including those involved in immune response, neurotransmitter metabolism, and vascular function.